规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
2-Methoxyestradiol (2-ME) (5-100 μM) 以浓度依赖性方式抑制纯化微管蛋白的组装,在 200 μM 2-Methoxyestradiol (2ME2) 时具有最大抑制 (60%)。 2-Methoxyestradiol 强烈降低存活间期 MCF7 细胞的平均微管生长速率、持续时间和长度以及总体动态,并具有 IC50 (1.2 μM) 有丝分裂抑制作用。这与其体外作用一致,并且似乎与微管解聚无关。 2. 2-甲氧基雌二醇可保护静止细胞,同时诱导多种活跃增殖的细胞类型的 G2-M 停滞和死亡。 2. 已证明,大量的甲基雌二醇通过与秋水仙碱位点或其附近的微管蛋白结合并抑制微管组装而使细胞内的微管解聚[1]。在缺氧条件下培养的细胞中,2-甲氧基雌二醇 (2-ME) 会降低 HIF-1α 和 HIF-2α 核标记。 2.甲氧基雌二醇降低HIF-1α蛋白的转录活性和水平。它是一种抗血管生成、抗增殖和促凋亡药物。与 DMSO 处理的细胞相比,用 10 μM 2-甲氧基雌二醇处理的 A549 细胞在 96 小时时的生长速率显着降低(分别为 66.2±7.2 和 101.2±2.3%;p=0.04)。当在常氧条件下用 10 μM 2-甲氧基雌二醇处理的细胞与低 O2 浓度(5.8±0.2%;p=0.003)下的细胞进行比较时,细胞凋亡显着增加 [2]。
|
---|---|
体内研究 (In Vivo) |
为了研究 2-甲氧基雌二醇 (2-ME2) 对葡萄膜炎进展的影响,C57BL/6 小鼠被随机分为两组并接受 IRBP 肽疫苗接种。从第0天到第13天,2ME2组腹腔注射15 mg/kg 2-甲氧基雌二醇,而对照组则接受载体注射。每组 5 只小鼠,2-甲氧基雌二醇(2ME2)组的疾病评分为 0.30±0.30,显着低于对照组的 2.09±0.28(p<0.05)[3]。每天给予 60-600 mg/kg 2-甲基雌二醇可对肿瘤发展产生剂量依赖性抑制。与媒介物治疗组 (86.5%) 相比,2-甲氧基雌二醇治疗组具有强哌莫硝唑阳性染色 (+++) 的细胞百分比要低得多(60 mg/kg/d 时为 36.0%,60 mg/kg/d 时为 0%) 200 和 600 毫克/公斤/天)。这可能是因为 2-甲氧基雌二醇治疗显着且剂量依赖性地抑制肿瘤的生长 [4]。
|
动物实验 |
9L-V6R cells are injected into the brains of Fischer 344 rats;
|
参考文献 |
[1]. Kamath K, et al. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther. 2006 Sep;5(9):2225-33.
[2]. Aquino-Gálvez A, et al. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep. 2016 Jan;35(1):577-83. [3]. Xu L, et al. 2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation. Biomed Res Int. 2016;2016:7948345. [4]. Kang SH, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 2006, 66(24),11991-11997. [5]. LaVallee TM, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptorsalpha and beta. Cancer Res. 2002 Jul 1;62(13):3691-7. [6]. Chen Y, et al. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008;15(1):171-182 |
分子式 |
C19H26O3
|
---|---|
分子量 |
302.4079
|
CAS号 |
362-07-2
|
相关CAS号 |
2-Methoxyestradiol-13C,d3;1217470-09-1;2-Methoxyestradiol-13C6;2-Methoxyestradiol-d5;358731-34-7
|
SMILES |
OC1=C(OC)C=C2[C@@]3([H])CC[C@]4(C)[C@@H](O)CC[C@@]4([H])[C@]3([H])CCC2=C1
|
化学名 |
(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
|
别名 |
NSC 659853; NSC-659853; NSC659853; 2-ME; 2-Methoxy Estradiol. 2-methoxyestradiol; US brand name: Panzem. Abbreviation: 2-ME2.
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: 60 mg/mL (198.4 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
|
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+corn oil:5mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3068 mL | 16.5338 mL | 33.0677 mL | |
5 mM | 0.6614 mL | 3.3068 mL | 6.6135 mL | |
10 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00592579 | Completed | Drug: 2-methoxyestradiol | Relapsed Multiple Myeloma Plateau Phase Multiple Myeloma |
CASI Pharmaceuticals, Inc | March 2001 | Phase 2 |
NCT00306618 | Completed | Drug: Panzem Nanocrystal Colloidal Dispersion |
Recurrent Glioblastoma Multiforme | CASI Pharmaceuticals, Inc. | January 2006 | Phase 2 |
NCT00328497 | Completed | Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) |
Carcinoid Tumor | CASI Pharmaceuticals, Inc. | May 2006 | Phase 2 |
NCT00481455 | Completed | Drug: Panzem NCD Drug: Temozolomide |
Recurrent Glioblastoma Multiforme | CASI Pharmaceuticals, Inc. | April 2007 | Phase 2 |
Treatment of 9L rat glioma cells with 2-methoxyestradiol (2ME2) at different oxygen concentration. Cancer Res. 2006 Dec 15;66(24):11991-7. td> |
A, a representative Gd-DTPA enhanced T1-weighted MRI image from each treatment group: left, before treatment; right, after treatment. B, summary of the tumor volume from the six rats in each group; all 24 rats before and after 2-methoxyestradiol treatment were measured by noninvasive post-contrast T1-weighted MRI. C, top left, acrylic brain matrices used to slice the rat brain into a 2-mm thickness from the tip of the frontal lobe of cerebrum (Start) to match with the MRI data that were scanned in the same orientation (End; bottom left). Cancer Res. 2006 Dec 15;66(24):11991-7. td> |
BLIs of HIF-1 activity are shown from three representative rats of each group at the end of 2-methoxyestradiol treatment. Right, scale of light intensity. Cancer Res. 2006 Dec 15;66(24):11991-7. td> |